VitriVax Raises $87M for Single-Dose Lyme Vaccine Trial
Theodore Randolph encountered a vaccine problem that began with the electricity supply. CU Boulder traces part of the inspiration for VitriVax to his volunteer work in Latin America, where unreliable refrigeration complicated vaccination. The Boulder company is now carrying that practical concern into a larger assignment: developing vaccines of its own.
VitriVax's $87M Series C, announced November 18, 2026, will fund its Lyme disease vaccine candidate's move toward a first-in-human trial and expand its proprietary pipeline. F-Prime, NEA, RA Capital Management and Sanofi Ventures co-led the financing, with Eli Lilly and Company and existing investors participating. The company describes the round as oversubscribed.
The financing connects a formulation platform to the clinical and manufacturing responsibilities of an owned vaccine business. VitriVax is pursuing single-dose delivery and improved temperature stability, advantages that could simplify vaccination if its candidates succeed. Human evidence for the lead Lyme program remains ahead of the company, alongside the work of turning those design goals into a usable product.
From formulation technology to an owned vaccine pipeline
VitriVax's financing changes the scope of the business around its ALTA platform. A technology supplier can help other developers improve a formulation; a company advancing proprietary candidates also has to choose indications, organize development and carry its products through clinical evaluation. CEO Romulo Colindres explicitly described that transition in the financing announcement, while retaining a role for global-health partnerships.
The leadership brings experience from different parts of that journey. Colindres's biography describes vaccine-development and medical-affairs work at GSK, including leading the medical team for the global Shingrix launch. Bryan Steadman, Chief Technical Officer, previously built manufacturing and quality organizations at biotech companies. Their respective backgrounds put clinical, market-access and manufacturing considerations inside the same management team.
The research lineage matters here, too. CU Boulder identifies Robert Garcea and Theodore Randolph as cofounders, connecting virology with chemical and biological engineering. Randolph's official biography describes a career in protein stabilization and delivery. Those origins help explain why the company's product proposition includes what happens to a vaccine during storage and administration, well beyond the choice of antigen alone.
How ALTA brings delivery into the product design
ALTA stands for Atomic Layering Thermostable Antigen and Adjuvant. On its technology page, VitriVax describes spray drying vaccine ingredients into a protective sugar-glass matrix, followed by atomic layer deposition to coat the resulting particles. The coating is intended to control release after injection, while the formulation is designed to improve temperature stability.
That approach gives the company a specific engineering brief: make delivery characteristics part of how the vaccine works. A proposed single-dose formulation could reduce the number of return appointments a clinic needs to organize. Improved stability could also make storage and transport easier. These are potential operating benefits, and their extent will depend on the performance and eventual requirements of each candidate.
For a health system, each additional appointment brings another scheduling and administration task. For a patient, it brings another date to remember and another trip to arrange. That is the commercial significance of the convenience claim: the experience of completing vaccination can affect how readily a product fits into ordinary care. VitriVax's program must still establish the human evidence needed to support its particular approach. The public materials do not provide a demonstrated clinical protection rate for the Lyme candidate or an approved storage and dosing label.
Lyme disease brings an existing prevention need
The CDC's Lyme vaccine overview says a vaccine for Lyme disease is currently unavailable. It also identifies Pfizer and Valneva's LB6V, formerly VLA15, among the candidates in human development. VitriVax is entering a field with other development programs and a proposed delivery distinction, while preparing for an earlier clinical milestone.
The scale of the burden requires careful language. A CDC estimate based on insurance claims suggests 476,000 people are treated for Lyme disease annually in the United States. That estimate measures treatment and differs from the more than 80,000 cases reported through annual surveillance. Neither figure is a count of future vaccine customers, and translating a prevention need into uptake will involve clinical evidence, recommendations and access.
The CDC describes another step after any FDA approval: working with the Advisory Committee on Immunization Practices on recommendations about who and where would benefit. For vaccine developers, that places the eventual product inside a broader decision process. The formulation, development evidence and proposed administration schedule will have to make sense to the institutions and people involved in vaccination, as well as to the investors funding the research.
The next handoff runs through manufacturing and human data
The Series C follows a $17.25M Series B announcement dated October 22, 2025, when Adjuvant Capital and RA Capital co-led financing for the formulation platform. The new announcement says that round was completed in September 2025. Separating the completion and announcement dates keeps the funding history clear without turning two descriptions of the same round into separate capital events.
VitriVax has also received grant and contract support. Its earlier financing release described Gates Foundation funding for manufacturing work, and the current company materials identify continuing global-health partnerships. Equity, grants and contract awards carry different obligations; adding them together would obscure the resources actually committed to each part of the business. The Series C announcement does not disclose a valuation or a complete lifetime equity total.
For the investors, the financing supports a company taking its delivery technology further into clinical product development. For Colindres and Steadman, it connects the manufactured formulation to the people who will administer it and collect the first human data. The original ambition survives that change in scale: a vaccine designed with the circumstances of its eventual use in mind, now moving through the development work that will determine what patients can actually receive.
Frequently Asked Questions
How could a single-dose Lyme vaccine change vaccination delivery?
A successful single-dose product could reduce return appointments and the work involved in completing a vaccination course. VitriVax is pursuing that design, but its Lyme candidate still needs human safety, immune-response and protection evidence.
What changes as VitriVax develops its own vaccine candidates?
VitriVax is expanding from formulation technology into a proprietary vaccine pipeline. The Series C funds clinical development of its lead Lyme candidate and additional programs, while the company continues partnership work.
How does the ALTA formulation approach work?
VitriVax describes spray drying vaccine ingredients into a protective sugar-glass matrix and applying a coating through atomic layer deposition. The platform is designed to improve temperature stability and control release after injection; product-specific clinical performance remains to be established.
How does VitriVax fit into Lyme vaccine development?
VitriVax is preparing its lead candidate for a first-in-human trial. The CDC says a Lyme vaccine is currently unavailable and identifies other candidates, including Pfizer and Valneva’s LB6V, already in human development.
What is known about VitriVax’s previous financing?
VitriVax announced a $17.25M Series B on October 22, 2025; its Series C release says the earlier round was completed in September 2025. Grants and contract support are separate from equity financing, and the Series C release does not provide a complete lifetime equity total.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved